Auspex Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Auspex Pharmaceuticals, Inc. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include AUSTEDO, AUSTEDO XR, and NOW IT'S YOUR MOVE. The owner is based in Parsippany, NJ.
400 Interpace Parkway
Parsippany, NJ 07054
Showing of trademarks Trademarks
Trademark Classifications
Auspex Pharmaceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Auspex Pharmaceuticals, Inc. have?
Auspex Pharmaceuticals, Inc. has 19 U.S. trademarks filed with the USPTO. Of these, 5 registered, 13 abandoned, 1 cancelled.
What trademark classes does Auspex Pharmaceuticals, Inc. file in?
Auspex Pharmaceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Auspex Pharmaceuticals, Inc.'s most well-known trademarks?
Auspex Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as AUSTEDO, AUSTEDO XR, and NOW IT'S YOUR MOVE. These are among 5 currently registered trademarks in the portfolio.
What is Auspex Pharmaceuticals, Inc.'s trademark registration success rate?
Auspex Pharmaceuticals, Inc. has a 26% trademark registration rate, with 5 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.